Mazdutide
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent · Phase 3 · Active, not recruiting · Enrollment 479
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide | n/r | n/r | n/r | n/r |
| IBI362 | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide: endpoint not reported
- IBI362: endpoint not reported